Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 15;130(18):3106-3114.
doi: 10.1002/cncr.35362. Epub 2024 May 6.

Statin use and risks of breast cancer recurrence and mortality

Hanbing Guo  1   2 , Kathleen E Malone  1   2 , Susan R Heckbert  2 , Christopher I Li  1   2
Affiliations
Free article

Statin use and risks of breast cancer recurrence and mortality

Hanbing Guo et al. Cancer. .
Free article

Abstract

Background: Preclinical evidence suggests improved breast cancer survival associated with statin use, but findings from observational studies are conflicting and remain inconclusive. The objective of this study was to assess the association between statin use after cancer diagnosis and cancer outcomes among breast cancer patients.

Methods: In this retrospective cohort study, 38,858 women aged ≥66 years who were diagnosed with localized and regional stage breast cancer from 2008 through 2017 were identified from the linked Surveillance, Epidemiology, and End Results Medicare database. Statin use was ascertained from Medicare Part D pharmacy claims data. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between post-diagnosis statin use and risks of breast cancer recurrence and breast cancer-specific mortality.

Results: Over a median follow-up of 2.9 years for recurrence and 3.7 years for mortality, 1446 women experienced a recurrence, and 2215 died from breast cancer. The mean duration of post-diagnosis statin use was 2.2 years. Statin use post-diagnosis was not associated with recurrence risk (HR, 1.05; 95% CI, 0.91-1.21), but was associated with a reduced risk of cancer-specific mortality (HR, 0.85; 95% CI, 0.75-0.96). The reduction was more pronounced in women with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer (HR, 0.71; 95% CI, 0.57-0.88).

Conclusions: These findings suggest that post-diagnosis statin use is associated with improved cancer-specific survival in women with breast cancer and should be confirmed in randomized trials of statin therapy in breast cancer patients.

Keywords: SEER‐Medicare; breast cancer; statins; survival.

PubMed Disclaimer

References

REFERENCES

    1. Salami JA, Warraich H, Valero‐Elizondo J, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2017;2(1):56‐65. doi:10.1001/jamacardio.2016.4700
    1. Grabarek BO, Boroń D, Morawiec E, et al. Crosstalk between statins and cancer prevention and therapy: an update. Pharmaceuticals. 2021;14(12):1220. doi:10.3390/ph14121220
    1. Ahmadi M, Amiri S, Pecic S, et al. Pleiotropic effects of statins: a focus on cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165968. doi:10.1016/j.bbadis.2020.165968
    1. Longo J, van Leeuwen JE, Elbaz M, Branchard E, Penn LZ. Statins as anticancer agents in the era of precision medicine. Clin Cancer Res. 2020;26(22):5791‐5800. doi:10.1158/1078‐0432.ccr‐20‐1967
    1. Tilija Pun N, Jeong CH. Statin as a potential chemotherapeutic agent: current updates as a monotherapy, combination therapy, and treatment for anti‐cancer drug resistance. Pharmaceuticals. 2021;14(5):470. doi:10.3390/ph14050470

Substances